Table 4.
AEs of LEN-TACE sequential therapy and LEN monotherapy
| AEs | LEN-TACE (n = 63) |
LEN monotherapy (n = 63) |
|||
|---|---|---|---|---|---|
| any grade, n (%) | grade ≥3, n (%) | any grade, n (%) | grade ≥3, n (%) | ||
| Fatigue | 30 (47.6) | 1 (1.6) | 24 (38.1) | 4 (6.3) | |
| Hypertension | 29 (46.0) | 7 (11.1) | 24 (38.1) | 5 (7.9) | |
| Decreased appetite | 27 (42.9) | 1 (1.6) | 21 (33.3) | 4 (6.3) | |
| Proteinuria | 25 (39.7) | 1 (1.6) | 27 (42.9) | 3 (4.8) | |
| Hypothyroidism | 22 (34.9) | 0 (0.0) | 23 (36.5) | 1 (1.6) | |
| Hand-foot skin reaction | 22 (34.9) | 4 (6.3) | 22 (34.9) | 2 (3.2) | |
| Liver dysfunction | 22 (34.9)* | 5 (7.9) | 12 (19.0) | 2 (3.2) | |
| Diarrhea | 13 (20.6) | 1 (1.6) | 7 (11.1) | 1 (1.6) | |
| Hoarseness | 10 (15.9) | 0 (0.0) | 10 (15.9) | 0 (0.0) | |
| Decreased weight | 10 (15.9) | 0 (0.0) | 7 (11.1) | 0 (0.0) | |
| Pyrexia | 7 (11.1) | 4 (6.3) | 4 (6.3) | 1 (1.6) | |
| Thrombocytopenia | 1 (1.6) | 1 (1.6) | 1 (1.6) | 1 (1.6) | |
| Encephalopathy | 1 (1.6) | 1 (1.6) | 4 (6.3) | 0 (0.0) | |
| Pneumonia | 0 (0.0) | 0 (0.0) | 1 (1.6) | 1 (1.6) | |
Data are presented as n (%). LEN, lenvatinib; TACE, transarterial chemoembolization.
*
p < 0.05, compared with LEN alone.